Efficacy and Safety of Ponatinib According to Prior Approved Tyrosine Kinase Inhibitor (TKI) Therapy in Patients with Chronic Myeloid Leukemia in Chronic Phase (CP-CML): Results From the PACE Trial

MLA

Kim, Dong-Wook, et al. “Efficacy and Safety of Ponatinib According to Prior Approved Tyrosine Kinase Inhibitor (TKI) Therapy in Patients with Chronic Myeloid Leukemia in Chronic Phase (CP-CML): Results From the PACE Trial.” Blood, vol. 120, no. 21, Nov. 2012, p. 3749. EBSCOhost, https://doi.org/10.1182/blood.V120.21.3749.3749.

APA

Kim, D.-W., Cortes, J. E., Pinilla-Ibarz, J., le Coutre, P., Paquette, R., Chuah, C., Nicolini, F. E., Apperley, J., Khoury, H. J., Talpaz, M., DiPersio, J. F., DeAngelo, D., Abruzzese, E., Rea, D., Baccarani, M., Muller, M. C., Gambacorti-Passerini, C., Wong, S., Lustgarten, S., … Kantarjian, H. M. (2012). Efficacy and Safety of Ponatinib According to Prior Approved Tyrosine Kinase Inhibitor (TKI) Therapy in Patients with Chronic Myeloid Leukemia in Chronic Phase (CP-CML): Results From the PACE Trial. Blood, 120(21), 3749. https://doi.org/10.1182/blood.V120.21.3749.3749

Chicago

Kim, Dong-Wook, Jorge E. Cortes, Javier Pinilla-Ibarz, Philipp le Coutre, Ronald Paquette, Charles Chuah, Franck E. Nicolini, et al. 2012. “Efficacy and Safety of Ponatinib According to Prior Approved Tyrosine Kinase Inhibitor (TKI) Therapy in Patients with Chronic Myeloid Leukemia in Chronic Phase (CP-CML): Results From the PACE Trial.” Blood 120 (21): 3749. doi:10.1182/blood.V120.21.3749.3749.